TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Omnicell ( (OMCL) ).
On September 30, 2025, Omnicell, Inc.’s board of directors adopted the fourth amended and restated bylaws, effective immediately. These amendments enhance procedural mechanics and disclosure requirements for stockholder nominations and proposals, address matters related to Rule 14a-19 under the Exchange Act, clarify personal jurisdiction provisions, and make various updates, impacting the company’s governance and stakeholder engagement.
The most recent analyst rating on (OMCL) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.
Spark’s Take on OMCL Stock
According to Spark, TipRanks’ AI Analyst, OMCL is a Neutral.
Omnicell’s overall stock score is driven by a positive earnings call that highlights revenue growth and strategic initiatives. However, high valuation metrics and technical indicators suggest caution. Financial performance is stable but not exceptional, with challenges in revenue growth and operational efficiency. The absence of corporate events and a dividend yield further tempers the score.
To see Spark’s full report on OMCL stock, click here.
More about Omnicell
Omnicell, Inc. operates in the healthcare industry, providing medication management solutions and adherence tools for healthcare systems and pharmacies.
Average Trading Volume: 527,023
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.42B
See more data about OMCL stock on TipRanks’ Stock Analysis page.